Phase II Trial of Methylglyoxal-Bis (guanylhydrazone) (MGBG) in Patients with Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group (ECOG) Study

Phase II Trial of Methylglyoxal-Bis (guanylhydrazone) (MGBG) in Patients with Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group (ECOG) Study

Abstract Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer investigation 1990-01, Vol.8 (2), p.143-146
Hauptverfasser: Winter, Jane N., Ritch, Paul S., Rosen, Steven T., Oken, Martin M., Wolter, Janet M., Wiernik, Peter H., O'connell, Michael J.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Drug Evaluation
Humans
Middle Aged
Mitoguazone - adverse effects
Mitoguazone - therapeutic use
Multicenter Studies as Topic
Multiple Myeloma - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.
ISSN:0735-7907
1532-4192
DOI:10.3109/07357909009017559